Destiny Pharma (DEST); notes that APSIC guidelines recommend decolonising S. aureus
Guidelines warn of issues with antibiotic resistance highlighting the need for new approaches
Destiny notes that new guidelines from the Asia Pacific Society for Infection Control (APSIC) for the prevention of surgical site infections have been published in the peer-reviewed journal, Antimicrobial Resistance and Infection Control.
Read more...KEFI Minerals (KEFI); announces project equity, exploration licences and placing
KEFI announced that all the updated relevant shareholder and subscription agreements were distributed to its Ethiopian partners regarding the Tulu Kapi Gold Project
The agreements are expected to be duly executed and returned by the Ethiopian Government and ANS Mining Share Company allowing for subscriptions for equity into Tulu Kapi Gold Mines Share Company (TKGM), the project company.
Read more...Finsbury Growth Income Trust (FGT); announces issue of 150,000 and 40,000 new ordinary shares
Finsbury Growth & Income Trust has issued 150,000 and 40,000 new ordinary shares of 25p each
Finsbury Growth & Income Trust has issued 150,000 and 40,000 new ordinary shares of 25p each in accordance with its placing programme at a price of 907.50p per share and 912.00p per share, respectively. The shares rank pari passu with the existing ordinary shares in issue.
Read more...Fidelity Special Values (FSV); issues a total of 1,050,000 new ordinary shares
Fidelity Special Values has issued a total of 1,050,000 new ordinary shares of 5p each from its block listing authority of 15 January 2019
The trust issued 500,000 new ordinary shares at a price of 270.50p per share, 400,000 new ordinary shares at a price of 272.00p per share and 150,000 new ordinary shares at a price of 273.00p per share. These shares rank pari passu with the existing ordinary shares in issue.
Read more...Chemring Group (CHG); revenue increases 13% to £335.2m for FY 2019
Chemring Group announced its results for the year ended 31 October 2019. Underlying operating profit and PBT increased 42% and 58% to £44.0m and £39.4m, respectively
Chemring Group announced its results for the year ended 31 October 2019. Underlying operating profit and PBT increased 42% and 58% to £44.0m and £39.4m, respectively. Underlying EPS rose 62% to 11.2p and DPS increased 9% to 3.6p. Net debt was £75.7m as of 31 October 2019.
Read more...Fins Growth Inc Tst (FGT); issues 170,000 and 130,000 ordinary shares
Finsbury Growth & Income Trust issued 170,000 and 130,000 new ordinary shares of 25p each in accordance with its placing programme at a price of 892.25p per share and 893.50p per share, respectively
Finsbury Growth & Income Trust issued 170,000 and 130,000 new ordinary shares of 25p each in accordance with its placing programme at a price of 892.25p per share and 893.50p per share, respectively. The shares rank pari passu with the existing ordinary shares in issue.
Read more...Henderson Far East Income (HFEL); allots 200,000 ordinary shares at 352p per share
Henderson Far East Income has agreed to allot 200,000 ordinary shares at 352p per share, each fully paid under its block listing facility
Henderson Far East Income has agreed to allot 200,000 ordinary shares at 352p per share, each fully paid under its block listing facility. The NAV per ordinary share as of 11 December 2019 was 342.5p.
Read more...Fidelity Special Values (FSV); issues 900,000 ordinary shares at 271p per share
Fidelity Special Values issued 900,000 new ordinary shares of 5p each at a price of 271p per share from its block listing authority of 15 January 2019
Fidelity Special Values issued 900,000 new ordinary shares of 5p each at a price of 271p per share from its block listing authority of 15 January 2019. The shares rank pari passu with the existing ordinary shares in issue.
Read more...Hansa Investment Co (HAN); interim results: NAV decreases to 278.5p
Hansa Investment Company announced its interim report for the period ended 30 September 2019, showing that In the past six months, NAV decreased to 278.5p
Hansa returned -0.4% in H1 and -0.5% over the past 12 months on an NAV total return basis. The key performance indicators for the last one year were 7.6% for the MSCI ACWI NR Index, 13.4% for the FTSE UK Gilts All Stocks TR Index and 1.8% for UK CPI.
Read more...BioPharma Credit (BPCR); announces loan agreement with Sarepta Therapeutics
BioPharma Credit has entered into a definitive senior secured term loan agreement with Sarepta Therapeutics alongside BioPharma Credit Investments V LP (BioPharma-V)
BioPharma Credit has entered into a definitive senior secured term loan agreement with Sarepta Therapeutics alongside BioPharma Credit Investments V LP (BioPharma-V). Under the agreement, Biopharma Credit will invest up to US$350m in two tranches and BioPharma-V will invest up to an additional US$150m.
Read more...